Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-07-14

Clinical Trial Update: WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating WAL801CL (epinastine hydrochloride) dry syrup in pediatric perennial allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • WAL801CL (epinastine hydrochloride)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Rhinitis, Allergic, Perennial | Phase 3 | Status: COMPLETED